Dr. Vladimir Cmiljanovic
About
Dr. Vladimir Cmiljanovic is from Basel Metropolitan Area. Dr. Vladimir is currently Founder, Vice-Chairman and CEO of Rocketvax AG at Rocketvax AG, located in Basel, Switzerland. Dr. Vladimir also works as Founder, Chairman and CEO of Swiss Rockets AG at SWISS ROCKETS AG, a job Dr. Vladimir has held since Nov 2018. In Dr. Vladimir's previous role as a Founder, Vice-Chairman and CEO of Torqur AG at Torqur AG, Dr. Vladimir worked in Basel, Switzerland until Sep 2023. Prior to joining Torqur AG, Dr. Vladimir was a Founder, Chairman and CEO of Torpedo Pharmaceuticals AG at Torpedo Pharmaceuticals AG and held the position of Founder, Chairman and CEO of Torpedo Pharmaceuticals AG at Basel, Switzerland. Prior to that, Dr. Vladimir was a Founder, CEO and Vice-Chairman of the Board of Directors of PIQUR Therapeutics AG at Piqur AG, based in Basel, Basel-Town, Switzerland from Aug 2011 to May 2018. Dr. Vladimir started working as Founder TargImmune AG at TargImmune Therapeutics AG in Basel, Basel-Town, Switzerland in Jan 2016.
Go to finalscout.com and type Vladimir Cmiljanovic's name into the search box for a free email address. FinalScout is a professional database with more than 500 million business professionals and 200 million company executives.
Dr. Vladimir Cmiljanovic's current jobs
Development of the second-generation SARS-CoV-2 virus vaccine. At RocketVax, we use proprietary molecular biology and chemical technologies to develop novel live attenuated virus vaccines based on breakthrough genetic engineering. Leading Swiss expert scientists from immunology, virology, molecular biology, and epidemiology have joined forces to translate a novel development concept against the SARS-CoV-2 virus. This pathogen has already impacted countless lives worldwide into a vaccine of the next generation. www.rocketvax.com
The Swiss biotech company Swiss Rockets AG launched a unique business model to meet cancer research and infectious diseases challenges. It is developing several innovative active ingredients and medical devices to improve patients' well-being significantly. These include vaccines against breast cancer, immunotherapies against leukemia, active substances against HPV infections and cervical cancer, and new biopsy devices. Swiss Rockets AG is implementing a paradigm shift in healthcare. Cancer patients will benefit from the innovative treatment therapies developed using innovative and disruptive methods. Our team combines specialist knowledge and experience to efficiently and sustainably break new ground in cancer medicine and infectious diseases. www.swissrockets.com
Dr. Vladimir Cmiljanovic's past jobs
Founded in 2021, as a spin-off company of the Swiss start-up incubator, Swiss Rockets AG, TORQUR AG is a biopharmaceutical company developing best-in-class, next-generation cancer therapeutics targeting the PI3K-Akt-mTOR pathway.
Torpedo Pharmaceuticals AG is a company focused on the development of next-generation radioligand therapies for the treatment of cancer patients. Their scope involves researching and advancing innovative medical approaches that utilize radioligands to target and treat cancer cells. Radioligand therapies involve the use of radioactive compounds that selectively bind to specific receptors on cancer cells, delivering localized radiation to destroy cancerous tissue while minimizing damage to healthy cells. Torpedo Pharmaceuticals AG aims to improve the effectiveness and precision of cancer treatment, potentially offering new hope and options for cancer patients.
Founded in 2011, as a spin-off company of the University of Basel (Switzerland), PIQUR Therapeutics AG is a biopharmaceutical company developing best-in-class, next-generation cancer therapeutics targeting the PI3K-Akt-mTOR pathway.
TargImmune Therapeutics AG is a private Swiss-based biotechnology company focused on drug development using novel targeted immunotherapies against cancer. The Company’s principal technology is targeted RNA platform technology that utilizes a non-viral vector to target and to destroy cancer cells that over-express specific receptors while simultaneously eliciting an immune response against the cancer cells. www.rocketvax.com